Skip to main content
Sana Biotechnology, Inc. logo

Sana Biotechnology, Inc. — Investor Relations & Filings

Ticker · SANA ISIN · US7995661045 US Manufacturing
Open in API
Filings indexed 362 across all filing types
Latest filing 2026-05-15 Regulatory Filings
Country US United States of America
Listing US SANA

About Sana Biotechnology, Inc.

https://sana.com/

Sana Biotechnology, Inc. is a company that develops engineered cells as medicines to address the underlying causes of disease. Its core strategy involves two primary platforms: in vivo therapies designed to repair and control genes within a patient's existing cells, and ex vivo therapies that replace missing or damaged cells with new, functional ones. The company utilizes proprietary technologies, such as engineered fusogen proteins, for the targeted delivery of therapeutics. Sana's pipeline is focused on advancing drug candidates for a range of diseases, including diabetes, B-cell cancers, and B-cell related autoimmune disorders.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings
2026-05-15 English
S-8 - Sana Biotechnology, Inc. (0001770121) (Filer)
Regulatory Filings
2026-05-11 English
ARS - Sana Biotechnology, Inc. (0001770121) (Filer)
Annual Report
2026-04-24 English
DEF 14A - Sana Biotechnology, Inc. (0001770121) (Filer)
Proxy Solicitation & Information Statement
2026-04-24 English
8-K - Sana Biotechnology, Inc. (0001770121) (Filer)
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated April 22, 2026, reporting a change in the classification of a board director, Steven D. Harr, from Class I to Class III to rebalance the board classes. The key section is Item 5.02, which pertains to departure, election, or appointment of directors or officers. There is no financial data or report attached, and the content focuses solely on board management changes. Therefore, this filing fits the category of Board/Management Information (MANG). The document length is 3792 characters, which is consistent with a typical 8-K filing for management changes rather than a full report or announcement of a report.
2026-04-24 English
424B5 - Sana Biotechnology, Inc. (0001770121) (Filer)
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a stock offering of common shares. It details the terms of the offering, the parties involved, the use of proceeds, risk factors, and other information typical of a securities offering document. It is not a financial report, earnings release, management discussion, or any other type of corporate filing related to financial performance or governance. Instead, it is a capital raising document describing the issuance of new shares to an investor. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is a full prospectus supplement, not just an announcement or brief notice.
2026-04-13 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.